Clinical Trial Update: A Study of PF-08046052/SGN-EGFRd2 in Advanced Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update for PF-08046052/SGN-EGFRd2 in advanced solid tumors, including colorectal cancer, non-small cell lung cancer, squamous cell carcin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Non-small Cell Lung Cancer
• Pancreatic Ductal Adenocarcinoma
• Squamous Cell Carcinoma of the Head and Neck

Drugs mentioned

• PF-08046052 (PF-08046052)
• SGN-EGFRd2 (SGN-EGFRd2)

Snippet

Sponsor: Seagen, a wholly owned subsidiary of Pfizer | Conditions: Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung | Phase 1 | Status: ACTIVE_NOT_RECRUITING